Publication

Kelly KR, Espitia CM, Zhao W, Wu K, Visconte V, Anwer F, Calton CM, Carew JS, Nawrocki ST. 2018. Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy. Leukemia. 32:230–233. doi:10.1038/leu.2017.272.

Hadinger KP, Marshalek JP, Sheeran PS, Dayton PA, Matsunaga TO. 2018. Optimization of Phase-Change Contrast Agents for Targeting MDA-MB-231 Breast Cancer Cells. Ultrasound Med Biol. 44:2728–2738. doi:10.1016/j.ultrasmedbio.2018.08.003.

Sun V, Ercolano E, McCorkle R, Grant M, Wendel CS, Tallman NJ, Passero F, Raza S, Cidav Z, Holcomb M, et al. 2018. Ostomy telehealth for cancer survivors: Design of the Ostomy Self-management Training (OSMT) randomized trial. Contemp Clin Trials. 64:167–172. doi:10.1016/j.cct.2017.10.008.

Chipollini J, Necchi A, Spiess PE. 2018. Outcomes for Patients with Node-positive Penile Cancer: Impact of Perioperative Systemic Therapies and the Importance of Surgical Intervention. Eur Urol. 74:241–242. doi:10.1016/j.eururo.2018.04.025.

Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, Chung CH, Hernandez-Aya L, Lim AM, Chang ALS, et al. 2018. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. N Engl J Med. 379:341–351. doi:10.1056/NEJMoa1805131.

Famoso JM, Laughlin B, McBride A, Gonzalez VJ. 2018. Pentoxifylline and vitamin E drug compliance after adjuvant breast radiation therapy. Adv Radiat Oncol. 3:19–24. doi:10.1016/j.adro.2017.09.004.

Huberty J, Eckert R, Larkey L, Gowin K, Mitchell J, Mesa R. 2018. Perceptions of Myeloproliferative Neoplasm Patients Participating in an Online Yoga Intervention: A Qualitative Study. Integr Cancer Ther. 17:1150–1162. doi:10.1177/1534735418808595.

Blohm-Mangone K, Burkett NB, Tahsin S, Myrdal PB, Aodah A, Ho B, Janda J, McComas M, Saboda K, Roe DJ, et al. 2018. Pharmacological TLR4 Antagonism Using Topical Resatorvid Blocks Solar UV-Induced Skin Tumorigenesis in SKH-1 Mice. Cancer Prev Res (Phila). 11:265–278. doi:10.1158/1940-6207.CAPR-17-0349.

Javle M, Lowery M, Shroff RT, Weiss KH, Springfeld C, Borad MJ, Ramanathan RK, Goyal L, Sadeghi S, Macarulla T, et al. 2018. Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. J Clin Oncol. 36:276–282. doi:10.1200/JCO.2017.75.5009.

McGregor HCJ, Surman A, Fernandez A, Saeed M, Wilson M, Hetts S, Conrad M. 2018. Pilot Study of the Safety and Efficacy of Gallbladder Cryoablation in a Porcine Model: Midterm Results. J Vasc Interv Radiol. 29:340–344. doi:10.1016/j.jvir.2017.10.020.

Pozo K, Zahler S, Ithimatsu K, Carter A, Telange R, Wang S, Pfragner R, Fujimoto J, Grubbs E, Takahashi M, et al. 2018. Preclinical characterization of tyrosine kinase inhibitor-based targeted therapies for neuroendocrine thyroid cancer, Oncotarget, 9: 37662-37675.

Weihs KL, Wiley JF, Crespi CM, Krull JL, Stanton AL. 2018. Predicting future major depression and persistent depressive symptoms: Development of a prognostic screener and PHQ-4 cutoffs in breast cancer patients. Psychooncology. 27:420–426. doi:10.1002/pon.4472.

Snider JM, Snider AJ, Obeid LM, Luberto C, Hannun YA. 2018. Probing de novo sphingolipid metabolism in mammalian cells utilizing mass spectrometry. J Lipid Res. 59:1046–1057. doi:10.1194/jlr.D081646.

Parker SS, Cox C, Wilson JM. 2018. Rabs set the stage for polarity. Small GTPases. 9:116–129. doi:10.1080/21541248.2016.1277840.

Glassman CR, Parrish HL, Lee MS, Kuhns MS. 2018. Reciprocal TCR-CD3 and CD4 Engagement of a Nucleating pMHCII Stabilizes a Functional Receptor Macrocomplex. Cell Rep. 22:1263–1275. doi:10.1016/j.celrep.2017.12.104.

Ding J, Stopeck AT, Gao Y, Marron MT, Wertheim BC, Altbach MI, Galons J-P, Roe DJ, Wang F, Maskarinec G, et al. 2018. Reproducible automated breast density measure with no ionizing radiation using fat-water decomposition MRI. J Magn Reson Imaging. 48:971–981. doi:10.1002/jmri.26041.

Dolinko AV, Farland LV, Missmer SA, Srouji SS, Racowsky C, Ginsburg ES. 2018. Responses to fertility treatment among patients with cancer: a retrospective cohort study. Fertil Res Pract. 4:3. doi:10.1186/s40738-018-0048-2.

Shroff RT, Hendifar A, McWilliams RR, Geva R, Epelbaum R, Rolfe L, Goble S, Lin KK, Biankin AV, Giordano H, et al. 2018. Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious Mutation. JCO Precis Oncol. 2018. doi:10.1200/PO.17.00316.

He S, Dong G, Wu S, Fang K, Miao Z, Wang W, Sheng C. 2018. Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents. J Med Chem. 61:7245–7260. doi:10.1021/acs.jmedchem.8b00664.

Saylor J, Ma Z, Goodridge HS, Huang F, Cress AE, Pandol SJ, Shiao SL, Vidal AC, Wu L, Nickols NG, et al. 2018. Spatial Mapping of Myeloid Cells and Macrophages by Multiplexed Tissue Staining. Front Immunol. 9:2925. doi:10.3389/fimmu.2018.02925.

Loescher LJ, Stratton D, Slebodnik M, Goodman H. 2018. Systematic review of advanced practice nurses’ skin cancer detection knowledge and attitudes, clinical skin examination, lesion detection, and training. J Am Assoc Nurse Pract. 30:43–58. doi:10.1097/JXX.0000000000000004.

Shah N, Kumar S, Zaman N, Pan CC, Bloodworth JC, Lei W, Streicher JM, Hempel N, Mythreye K, Lee NY. 2018. TAK1 activation of alpha-TAT1 and microtubule hyperacetylation control AKT signaling and cell growth. Nat Commun. 9:1696. doi:10.1038/s41467-018-04121-y.

Padilla-Rodriguez M, Parker SS, Adams DG, Westerling T, Puleo JI, Watson AW, Hill SM, Noon M, Gaudin R, Aaron J, et al. 2018. The actin cytoskeletal architecture of estrogen receptor positive breast cancer cells suppresses invasion. Nat Commun. 9:2980. doi:10.1038/s41467-018-05367-2.

Petyuk VA, Chang R, Ramirez-Restrepo M, Beckmann ND, Henrion MYR, Piehowski PD, Zhu K, Wang S, Clarke J, Huentelman MJ, et al. 2018. The human brainome: network analysis identifies HSPA2 as a novel Alzheimer’s disease target. Brain. 141:2721–2739. doi:10.1093/brain/awy215.

Shroff RT, Yarchoan M, O’Connor A, Gallagher D, Zahurak ML, Rosner G, Ohaji C, Sartorius-Mergenthaler S, Parkinson R, Subbiah V, et al. 2018. The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma. Br J Cancer. 118:e2. doi:10.1038/bjc.2017.418.